miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

BOULDER -- Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced its merger with... Read More

Monday February 20, 2017 0 comments Tags: Boulder, miRagen Therapeutics, Signal Genetics, William S. Marshall

MiRagen Therapeutics, Signal Genetics sign merger agreement

MiRagen Therapeutics, Signal Genetics sign merger agreement

BOULDER --Miragen Therapeutics and California-based Signal Genetics, Inc. (Nasdaq: SGNL) today announced they have entered into a definitive merger agreement in which the stockholders of miRagen... Read More

Tuesday November 1, 2016 0 comments Tags: miRagen Therapeutics, Signal Genetics, William S. Marshall, Samuel D. Riccitelli

miRagen Therapeutics named to FierceBiotech's Fierce 15 List of most promising biotech firms

miRagen Therapeutics named to FierceBiotech's Fierce 15 List of most promising biotech firms

BOULDER - FierceBiotech has named miRagen Therapeutics one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. "Over the past... Read More

By: Steve Thursday September 20, 2012 0 comments Tags: biotechnology, Boulder, Fierce 15, FierceBiotech, microRNA, miRagen Therapeutics, Ryan McBride, Servier, William S. Marshall